VRB-101
EVOLVE-2
Verdiva Bio Dev Limited · Phase 2 · Completed · Enrollment 206
Participants reaching threshold, %
Source: Cited trial source. The denominator is the source figure, when it states one.
No selected arm reports a responder percent.
Show as table
| Arm | ≥5% | ≥10% | ≥15% | ≥20% |
|---|---|---|---|---|
| Schedule A: VRB-101 (Active Arm 1) | n/r | n/r | n/r | n/r |
| Schedule A: VRB-101 (Active Arm 2) | n/r | n/r | n/r | n/r |
| Schedule A: VRB-101 (Active Arm 3) | n/r | n/r | n/r | n/r |
| Schedule B: VRB-101 (Active Arm 4) | n/r | n/r | n/r | n/r |
| Schedule B: VRB-101 (Active Arm 5) | n/r | n/r | n/r | n/r |
| Pooled Placebo | n/r | n/r | n/r | n/r |
Not shown
- Schedule A: VRB-101 (Active Arm 1): endpoint not reported
- Schedule A: VRB-101 (Active Arm 2): endpoint not reported
- Schedule A: VRB-101 (Active Arm 3): endpoint not reported
- Schedule B: VRB-101 (Active Arm 4): endpoint not reported
- Schedule B: VRB-101 (Active Arm 5): endpoint not reported
- Pooled Placebo: endpoint not reported